- Home
- GLXG vs ATNM Comparison
GLXG vs ATNM Comparison
Compare GLXG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- ATNM
- Stock Information
- Founded
- GLXG 2013
- ATNM 2000
- Country
- GLXG Hong Kong
- ATNM United States
- Employees
- GLXG N/A
- ATNM N/A
- Industry
- GLXG
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- ATNM Health Care
- Exchange
- GLXG NYSE
- ATNM Nasdaq
- Market Cap
- GLXG 70.4M
- ATNM 56.5M
- IPO Year
- GLXG 2024
- ATNM N/A
- Fundamental
- Price
- GLXG $0.72
- ATNM $1.22
- Analyst Decision
- GLXG
- ATNM Strong Buy
- Analyst Count
- GLXG 0
- ATNM 4
- Target Price
- GLXG N/A
- ATNM $8.75
- AVG Volume (30 Days)
- GLXG 402.7K
- ATNM 371.5K
- Earning Date
- GLXG 02-16-2025
- ATNM 11-14-2024
- Dividend Yield
- GLXG N/A
- ATNM N/A
- EPS Growth
- GLXG N/A
- ATNM N/A
- EPS
- GLXG 0.04
- ATNM N/A
- Revenue
- GLXG $3,858,088.00
- ATNM $81,000.00
- Revenue This Year
- GLXG N/A
- ATNM $186.10
- Revenue Next Year
- GLXG N/A
- ATNM $19,248.94
- P/E Ratio
- GLXG $17.90
- ATNM N/A
- Revenue Growth
- GLXG N/A
- ATNM N/A
- 52 Week Low
- GLXG $0.70
- ATNM $1.10
- 52 Week High
- GLXG $16.93
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- ATNM 40.77
- Support Level
- GLXG N/A
- ATNM $1.10
- Resistance Level
- GLXG N/A
- ATNM $1.29
- Average True Range (ATR)
- GLXG 0.00
- ATNM 0.10
- MACD
- GLXG 0.00
- ATNM 0.01
- Stochastic Oscillator
- GLXG 0.00
- ATNM 39.87
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.